TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Cetera Investment Advisers

Cetera Investment Advisers cut its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 1.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 52,199 shares of the biopharmaceutical company’s stock after selling 512 shares during the period. Cetera Investment Advisers’ holdings in TG Therapeutics were worth $1,571,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in TG Therapeutics by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company’s stock worth $469,454,000 after purchasing an additional 209,190 shares during the period. Clearbridge Investments LLC acquired a new position in TG Therapeutics in the 4th quarter worth $55,237,000. Northern Trust Corp lifted its holdings in TG Therapeutics by 8.6% in the 4th quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company’s stock worth $46,141,000 after buying an additional 120,785 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of TG Therapeutics by 7.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company’s stock valued at $38,212,000 after purchasing an additional 84,904 shares in the last quarter. Finally, Invesco Ltd. raised its stake in shares of TG Therapeutics by 1.2% in the 4th quarter. Invesco Ltd. now owns 929,743 shares of the biopharmaceutical company’s stock valued at $27,985,000 after purchasing an additional 10,989 shares in the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

TGTX has been the topic of several research reports. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 4th. HC Wainwright restated a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.80.

TG Therapeutics Stock Performance

NASDAQ TGTX opened at $35.47 on Wednesday. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The firm has a market capitalization of $5.63 billion, a price-to-earnings ratio of -354.66 and a beta of 2.21. The company’s fifty day moving average is $38.51 and its two-hundred day moving average is $34.09. TG Therapeutics, Inc. has a 52-week low of $15.16 and a 52-week high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.16). The company had revenue of $120.86 million for the quarter, compared to analyst estimates of $117.07 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm’s revenue for the quarter was up 90.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.07) earnings per share. Equities research analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.